Cyriel Y Ponsioen Selected Research

Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

1/2024	Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.
1/2020	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.
1/2020	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
3/2019	Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
8/2018	TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism.
1/2017	Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.
1/2017	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
3/2016	Incidence and Severity of Prepouch Ileitis: A Distinct Disease Entity or a Manifestation of Refractory Pouchitis?
1/2016	Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
10/2014	Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cyriel Y Ponsioen Research Topics

Disease

20	Sclerosing Cholangitis 03/2024 - 08/2010
20	Ulcerative Colitis 09/2023 - 03/2010
20	Crohn Disease (Crohn's Disease) 07/2023 - 08/2010
15	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2024 - 06/2002
12	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2023 - 05/2014
9	Fibrosis (Cirrhosis) 03/2024 - 11/2015
8	Neoplasms (Cancer) 10/2021 - 12/2013
7	Disease Progression 01/2018 - 07/2012
6	Necrosis 07/2023 - 01/2014
5	Liver Diseases (Liver Disease) 03/2024 - 06/2013
5	Fistula 07/2023 - 08/2015
5	Inflammation (Inflammations) 09/2021 - 08/2013
4	Colitis 01/2023 - 12/2013
4	Cholangitis 12/2021 - 02/2012
3	Pathologic Constriction (Stenosis) 10/2019 - 01/2018
2	Cholangiocarcinoma 11/2023 - 10/2021
2	Klatskin Tumor 07/2023 - 01/2023
2	Pouchitis 09/2021 - 03/2016
2	Sepsis (Septicemia) 12/2019 - 03/2013
2	Bile Duct Diseases (Bile Duct Disease) 01/2018 - 08/2010
2	End Stage Liver Disease 04/2016 - 05/2015
2	Infections 10/2014 - 02/2012
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2024
1	Hepatic Encephalopathy 03/2024
1	Jaundice (Icterus) 01/2022
1	Non-alcoholic Fatty Liver Disease 11/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2021
1	Liver Neoplasms (Liver Cancer) 11/2021
1	Chronic Hepatitis C 11/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Liver Failure 01/2018
1	Rare Diseases (Rare Disease) 01/2018
1	Metabolic Bone Diseases (Osteopenia) 01/2018
1	Thrombocytopenia (Thrombopenia) 02/2016
1	Vitamin D Deficiency 10/2014
1	Opportunistic Infections (Opportunistic Infection) 10/2014

Drug/Important Bio-Agent (IBA)

11	Biomarkers (Surrogate Marker)IBA 03/2024 - 12/2013
11	Infliximab (Remicade)FDA Link 10/2020 - 03/2013
9	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2023 - 12/2015
7	Alkaline PhosphataseIBA 01/2023 - 12/2014
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 08/2013
5	BilirubinIBA 01/2022 - 12/2014
4	C-Reactive ProteinIBA 11/2021 - 12/2013
4	Adalimumab (Humira)FDA Link 01/2018 - 02/2014
3	vedolizumabIBA 01/2024 - 01/2020
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 10/2020
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2021 - 02/2012
3	Leukocyte L1 Antigen Complex (Calgranulin)IBA 11/2021 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 10/2021 - 08/2013
3	AntibodiesIBA 08/2018 - 06/2002
3	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 06/2013
2	MetalsIBA 07/2023 - 01/2023
2	IntegrinsIBA 09/2021 - 01/2020
2	Immunologic Factors (Immunomodulators)IBA 10/2020 - 10/2019
2	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 08/2013
2	Immunoglobulin G (IgG)IBA 08/2018 - 05/2014
2	2-mercaptopurineIBA 01/2018 - 06/2013
2	EnzymesIBA 01/2015 - 06/2002
2	Bile Acids and Salts (Bile Acids)IBA 08/2010 - 03/2010
2	GTP-Binding Proteins (G-Protein)IBA 08/2010 - 03/2010
1	Glial Fibrillary Acidic ProteinIBA 03/2024
1	Butyrates (Butyrate)IBA 09/2023
1	6-propylchromone-2-carboxylic acid (PCCA)IBA 07/2023
1	PlasticsIBA 07/2023
1	Janus KinasesIBA 01/2023
1	tofacitinibIBA 01/2023
1	Janus Kinase InhibitorsIBA 01/2023
1	Ustekinumab (CNTO 1275)FDA Link 11/2021
1	CollagenIBA 11/2021
1	Formaldehyde (Formol)FDA Link 10/2020
1	DNA (Deoxyribonucleic Acid)IBA 10/2020
1	ParaffinIBA 10/2020
1	GlucocorticoidsIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	SteroidsIBA 10/2019
1	Messenger RNA (mRNA)IBA 01/2018
1	Thioguanine (Tioguanine)FDA Link 01/2018
1	Prednisone (Sone)FDA LinkGeneric 01/2018
1	Procollagen N-Endopeptidase (Procollagen Peptidase)IBA 01/2018
1	Interleukin-8 (Interleukin 8)IBA 01/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2016

Therapy/Procedure

35	Therapeutics 01/2024 - 07/2012
13	Liver Transplantation 01/2023 - 06/2013
9	Restorative Proctocolectomy 09/2021 - 02/2012
4	Stents 11/2023 - 01/2018
3	Fecal Microbiota Transplantation 09/2023 - 07/2015
3	Colectomy 02/2017 - 02/2012
3	Appendectomy 01/2016 - 03/2015
2	Radiofrequency Ablation 11/2023 - 01/2023
2	Duration of Therapy 12/2021 - 10/2020
2	Transplantation 01/2020 - 01/2017
1	Transjugular Intrahepatic Portasystemic Shunt 03/2024
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 03/2024
1	Drug Therapy (Chemotherapy) 10/2021
1	Contraindications 01/2018
1	Activities of Daily Living (ADL) 01/2018
1	Intravenous Infusions 02/2016
1	Ileostomy 11/2015
1	Combined Modality Therapy 08/2015